Sign In
Buy BCLI
$0.770
-0.0217 (-2.74%)
At Close: Jun 03, 2026
Former FDA Associate Commissioner Peter Pitts and BrainStorm's Chaim Lebovits argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine NEW YORK, June 2
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
07:45am, Thursday, 28'th May 2026
Former Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol Assessment NEW YORK, May 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
08:00am, Tuesday, 19'th May 2026
$2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE Trial NEW YORK, May 19, 2026 /PRNewswire/ -- May 19, 2026 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer
BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
04:05pm, Friday, 15'th May 2026
NEW YORK, May 15, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial re
Comparing Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Zealand Pharma A/S (OTCMKTS:ZLDPF)
04:10am, Saturday, 18'th Apr 2026
Brainstorm Cell Therapeutics (NASDAQ: BCLI - Get Free Report) and Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) are both medical companies, but which is the superior business? We will contrast
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened
03:43am, Wednesday, 08'th Apr 2026
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving avera
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
04:01pm, Tuesday, 31'st Mar 2026
Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidence Company highlights durable long-term survival in Expanded Access Program (EAP) cohort supportin
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Price Passes Above 200-Day Moving Average – Should You Sell?
02:10am, Tuesday, 31'st Mar 2026
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.65 and t
Brainstorm Cell Therapeutics (BCLI) Expected to Announce Quarterly Earnings on Monday
02:14am, Monday, 23'rd Mar 2026
Brainstorm Cell Therapeutics (NASDAQ: BCLI - Get Free Report) is anticipated to release its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
06:22am, Thursday, 26'th Feb 2026
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has enter
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
06:00am, Friday, 20'th Feb 2026
NEW YORK, Feb. 20, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entere
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
04:30pm, Friday, 14'th Nov 2025
NEW YORK , Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial
Halper Sadeh LLC Encourages Brainstorm Cell Therapeutics Inc. Shareholders to Contact the Firm to Discuss Their Rights
07:20am, Monday, 27'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Brainstorm Cell Therapeutics Inc. (OTCMKTS: BCLI) breached their fi
Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2025 Earnings Call Transcript
01:29pm, Thursday, 14'th Aug 2025
Brainstorm Cell Therapeutics Inc. (OTC:BCLI) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Alla Patlis - Interim CFO & Controller Chaim Lebovits - President & CEO Ib
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
07:02am, Thursday, 14'th Aug 2025
Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK , Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading de
